Targeted therapy better for repeat kidney cancer patients than FDA-approved counterpart

Kidney cancer patients who had already tried two or three different treatments had improved chances of preventing cancer progression with an experimental drug called tivozanib compared to an alternative approved by the U.S. Food and Drug Administration, according to a City of Hope-led study. “This agent has shown in clinical trials to be effective in delaying cancer growth beyond established […]

Continue reading »